e19570 Background: Burkitt lymphoma (BL) is one of the most aggressive B-cell lymphoma types. However, it has a high cure rate which varies depending on the different clinical pathological characteristics. We aimed to evaluate the prognostic factors for survival in patients with BL. Methods: We performed a retrospective study at the National Institute of Neoplastic Diseases in Peru from 2000 to 2014. We reviewed medical records of patients with BL aged 15 years and above. The data collected were based on clinical characteristics, treatment and survival. Patients with human immunodeficiency virus (HIV) infection were considered for analysis. The overall survival (OS) and progression-free survival (PFS) rates were estimated using the Kaplan-Meier method, the survival curves according to the clinical characteristics were compared using the log-rank test. Prognostic factors were determined using Cox regression modeling. Results: A total of 55 patients had sufficient data for analysis. The median age was 34 years (range 15-73), 78% were male and 73% had B symptoms. Lymph node involvement (LNI) as primary site was present in 89% of patients, of which 43% and 39% were retroperitoneal and cervical LNI, respectively. Bulky mass ( > 10cm) was reported in 73% of the patients. Advanced disease was found in 78% (stage III 31%, IV 47%). Elevated serum LDH level was seen in 60% of cases; and 33% had HIV infection. Intensive chemotherapy was given to 80% (44) of patients, with 34% receiving multi-agent acute lymphoblastic leukemia protocol, 22.8% DA-EPOCH, 18% CODOX-M IVAC, and 11.4% Hyper-CVAD. No patient received rituximab in the front-line setting. The complete response rate was 39%. With a median follow-up of 9 years, the median OS for the entire cohort (N = 55) was 6.9 months (range 1.9-11.9) with a 5-year survival rate of 26.3%. The median OS for the treated patients (N = 44) was 11.3 months (range 3.2-19.4) with a 5-year survival rate of 30.6%. The median PFS was 7.3 months, and the 5-year OFS rate was 30.8%. 5-year OS rates were worse in those with B symptoms (66% vs. 12.5%, p = 0.003), elevated serum LDH level (44.1% vs. 15.2%, p = 0.043), albumin < 3.5 g/dL (36.5% vs. 15.4%, p = 0.023), beta-2 microglobulin > 2.5 mg/L (41.4% vs. 20%, p = 0.029), and HIV infection (31% vs. 16.7%, p = 0.006). In the multivariate analysis, the presence of B symptoms (HR 5.4 [2.2, 13.4], p < 0.001) and HIV infection (HR 2.8 [1.5, 5.4], p = 0.002) were both factors associated with worse survival. Conclusions: In our study, the 5-year OS rate of patients with BL treated with chemotherapy was shorter (30.6%) than in developed countries. The response rates were also lower than in other studies. Inclusion of rituximab is needed to improve response rates. Presence of B symptoms and HIV infection were associated to worse survival.